Stay updated with breaking news from Xudative Armd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The recently approved 8-mg dose of aflibercept has shown sustained improvement in vision and anatomical markers out to 96 weeks, according to updated clinical trial results.
A real-world study of faricimab in neovascular age-related macular degeneration showed visual and anatomical improvement in line with phase 3 trials in treatment-naive and previously treated eyes.
Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.
An extension study found no cases of occlusive retinal vasculitis after 23,000 injections of pegcetacoplan, but a panel received more reports of the complication and dealt with conflicts of interest.
Recalled in 2022, a port delivery system for ranibizumab to treat wet AMD demonstrated that vision and retinal anatomy remained stable in patients who had the device for 5 years.